Muhammet Tanc is a medicinal chemist with 15 years of experience in cancer drug discovery and radiopharmaceutical innovation.
Before founding NTx, he held research roles at King’s College London, the University of Antwerp, and the University of Florence. His work focused on small-molecule therapeutics, radiopharmaceutical development, and target validation.
He has co-authored more than 50 publications in the field, holds two patents, and is a two-time recipient of the Marie Curie Fellowship.
At Nuclide Therapeutics, he leads company strategy and investor engagement, with a focus on converting high-value science into clinically meaningful and commercially scalable oncology products.
He is particularly focused on advancing innovative therapeutic platforms and building multidisciplinary collaborations that accelerate the development of precision radioligand therapies.
